No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
DaVita Inc. specializes in delivering vital kidney dialysis treatments to individuals afflicted with chronic kidney failure. The company manages numerous outpatient dialysis clinics, where it not only conducts dialysis sessions but also offers essential laboratory testing services. Its comprehensive offerings extend to outpatient, hospital inpatient, and at-home hemodialysis. Furthermore, DaVita operates its own clinical laboratories, performing standard dialysis-related tests and other prescribed analyses for ESRD patients, alongside providing management and administrative support to its network of outpatient centers. Beyond core dialysis, DaVita delivers a suite of integrated care services, including disease management for approximately 23,000 patients (within both risk-based and other integrated arrangements), vascular access procedures, clinical research initiatives, physician consultation, and holistic kidney care programs. By the close of 2021, DaVita maintained a substantial presence, with 2,815 outpatient dialysis facilities across the United States serving around 203,100 patients, and an additional 339 centers in 10 international markets supporting roughly 39,900 patients. In the U.S., it also delivered acute inpatient dialysis services, complete with laboratory support, in approximately 850 hospitals. Originally incorporated in 1994 and headquartered in Denver, Colorado, the company adopted its current name, DaVita Inc., in September 2016, having previously operated as DaVita HealthCare Partners Inc.
www.davita.comNo one on the platform currently holds 0I7E.L.
No tracked institution reports a position in 0I7E.L as of their last filing.
No one on the platform has traded 0I7E.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.6% | 10.5% | 9.4% | — | — | — |
| Rev. Growth % | 6.5% | 3.4% | ||||
| Profit Margin % | 5.5% | 6.3% | 6.1% | |||
| Free Cash Flow Margin % | 9.6% | 10.6% | 10.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $14.1B | +4.1% | $14.85 | $14.39–$15.53 | — | 1 |
| 2027 | $14.5B | +2.7% | $17.06 | $16.53–$17.84 | — | 1 |
| 2028 | $14.8B | +2.0% | $19.88 | $19.26–$20.79 | — | 1 |
| 2029 | $15.9B | +7.7% | $18.12 | $17.56–$18.95 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $3.88 | $4.02 | +3.6% |
| 2026-05-05 | $2.33 | $2.87 | +23.2% |
| 2026-02-02 | $3.24 | $3.40 | +4.9% |
| 2025-10-29 | $3.22 | $2.04 | -36.6% |
| 2025-08-05 | $2.77 | $2.58 | -6.9% |
| 2025-05-12 | $1.95 | $2.00 | +2.6% |
| 2025-02-13 | $2.13 | $3.09 | +45.1% |
| 2024-10-30 | $2.72 |
| $2.50 |
| -8.1% |
| +0.62% |
| $15.1B |
| — |
| 0J2O.LHalozyme Therapeutics, Inc. | $106.52 | -1.73% | $12.6B | — |
| 0JZ2.LMasimo Corporation | $179.96 | +0.01% | $9.5B | — |
Source: Financial Modeling Prep · peers by sector/industry